BIOLOGICAL TESTING FACILITY - PRECLINICAL DEVELOPMENT OF CONTRACEPTIVES

生物测试设施 - 避孕药具的临床前开发

• 批准号: 9922173
• 负责人: TOUFAN PARMAN
• 金额: $ 39.54万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-27 至 2019-09-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9922173
• 关键词: Animals; Area; Biological Assay; Biological Testing; Chemicals; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive Devices; Contraceptive methods; Contractor; Development; Documentation; Drug Formulations; Endocrine; Enrollment; Evaluation; Excretory function; Formulation; Implant; In Vitro; Injectable; Investigational Drugs; Investigational New Drug Application; Metabolism; Methods; Mission; National Institute of Child Health and Human Development; Oral; Ovulation; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Plasma; Play; Process; Production; Program Development; Protocols documentation; Reporting; Research Personnel; Research Support; Role; Route; Safety; System; Testing; Therapeutic Agents; Time; Toxic effect; Toxicology; Woman; absorption; chemical synthesis; clinical lot; clinical material; design; drug candidate; drug development; in vitro Assay; in vivo; lot production; men; novel therapeutics; pharmacokinetics and pharmacodynamics; pre-clinical; preclinical development; product development; programs; recruit; research clinical testing; sperm cell; sperm function; stability testing

The Contraceptive Development Program (CDP) within NICHD supports research to develop compounds that can disrupt normal ovulation, sperm production or sperm function so that safe, effective and inexpensive contraceptives can be developed for men or women. The Biological Testing Facility (BTF) is designed to permit rapid evaluation of new compositions-of-matter, drug formulations, delivery systems, and devices for contraceptive and endocrine activity. The BTF provides overall project management and the capabilities to support all phases of preclinical activities pursuant to development of new contraceptive methods: these include, but are not limited to in vitro and in vivo assays, plasma and microsomal stability studies, absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetic (PK) and pharmacodynamic (PD) profiling, animal activities and studies, manufacture of active pharmaceutical ingredients (APIs), process and product development, formulation, clinical lot production, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications. Compounds formulated by the BTF are prepared under current Good Manufacturing Practices (cGMP) to allow clinical evaluation in the CDP Contraceptive Clinical Trials Network (CCTN). The CCTN investigators have develop protocols to evaluate the drug candidates identified as high priority by the Program. The BTF has been working with the CORs for the Chemical Synthesis Facility and the CCTN and with the investigators in the CCTN to develop and test the appropriate formulations for clinical batches of the candidate compounds. The next clinical study for each candidate drug is dependent on timely receipt of clinical batches to begin the process of recruitment and enrollment. Drugs that are currently in ongoing clinical trials require stability testing of the clinical formulations. The Biological Testing Facility plays a critical role in the drug development mission of the CDP.

NICHD的避孕开发方案支持研究开发能够破坏正常排卵、精子生成或精子功能的化合物，以便为男性或女性开发安全、有效和廉价的避孕药具。生物试验设施（BTF）的目的是允许快速评估新的物质组合物，药物配方，输送系统，以及避孕和内分泌活动的装置。BTF提供全面的项目管理和能力，以支持根据新避孕方法开发的临床前活动的所有阶段：这些包括但不限于体外和体内分析，血浆和微粒体稳定性研究，吸收、分布、代谢、排泄和毒性（ADMET），药代动力学（PK）和药效学（PD）分析，动物活动和研究，活性药物成分（API）的生产、工艺和产品开发、配方、临床批量生产、临床前使能研究以及导致提交研究性新药（IND）申请的相关任务。由BTF配制的化合物根据现行药品生产质量管理规范（cGMP）制备，以便在CDP避孕临床试验网络（CCTN）中进行临床评价。CCTN研究人员已经制定了方案，以评估该计划确定为高优先级的候选药物。BTF一直在与化学合成机构和CCTN的COR以及CCTN的研究人员合作，开发和测试候选化合物临床批次的适当配方。每种候选药物的下一项临床研究取决于是否及时收到临床批次，以开始招募和入组过程。目前正在进行临床试验的药物需要进行临床制剂的稳定性试验。生物试验机构在CDP的药物开发使命中发挥着关键作用。